Acadia Pharma (ACAD) Misses Q1 EPS by 10c; Offers FY22 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Acadia Pharmaceuticals Reports First Quarter 2022 Financial Results
May 4, 2022 4:05 PM EDT- 1Q22 net sales of $115.5 million, an 8% increase over 1Q21
- Reiterating FY22 net sales guidance of $510 to $560 million
- FDA Advisory Committee meeting to review sNDA for pimavanserin for the treatment of ADP scheduled for June 17, 2022
SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the first quarter ended March 31, 2022.
NUPLAZID continued to deliver year over year growth in the first quarter of 2022, said Steve Davis, Chief Executive Officer. In the near... More
